

Prof Alexander M.M. Eggermont, MD, PhD

Chief Scientific Officer, Princess Máxima Center for Pediatric Oncology, and Professor of Clinical&Translational Immunotherapy at the UMCU, Utrecht University, Utrecht, NL. Past Director General the Gustave Roussy Cancer Institute, France (2010-2019); Emeritus Professor Oncology, University Paris-Saclay, France; Emeritus Professor of Surgical Oncology, ErasmusMC, NL

Coordinator Comprehensive Cancer Center Program, Deutsche KrebsHilfe, and Strategic Advisor at the DKFZ-NCT Heidelberg for National Center for Tumors Program

Professor Eggermont is a melanoma specialist and immunotherapy development specialist. He trained at the NIH-NCI Surgery Branch with Steve Rosenberg and obtained a PhD in Tumor Immunology; He was the international PI of the pivotal trials that resulted in approval of TNFalpha by EMA for locally advanced extremity sarcomas to achieve limb salvage (1998), for adjuvant therapy in melanoma FDA approvals with PEG-IFN-2b (2011), ipilimumab (2015) and pembrolizumab (2018). He is involved in multiple immunotherapy development trials. **Scientific Output:** > 1000 publications. **H-index/citations:** 125 ; >80000 citations

International Positions: President EACS European Academy Cancer Sciences (2010-2019), President Cancer Core Europe (2014-2019), President ECCO (2009-2011), President EORTC (2006-2009), Member Board of ASCO (2008-2010), ESMO executive board (2014-2018). Editor-in-Chief of Eur Journal of Cancer (2011-....)

Selection professional awards: Joseph Maisin Chair, Catholic University Louvain, Belgium (2001); ASCO Statemans Award (2010); Michiel Van Vloten Award, (2016); John Wayne Award, Society Surgical Oncology (2018); Doctorate Honoris Causa (University Essen, D) (2018); Honorary Chair KAZIOR (Kazakh Inst Oncology and Radiotherapy)(2019); Deutsche KrebsHilfe Cancer Award (2020)

Societal Awards

Légion d'Honneur, France ; Presidential Medal, Kazakhstan